1. Medtech Insight
  2. >>Archive

Spiracur's portable wound therapy device CE marked

 
• By Madeleine Armstrong

Spiracur has CE marked its "ultraportable" SNaP wound care system for sale in Europe. The single-use negative pressure device removes small amounts of fluid from ulcers, surgically closed incisions, and chronic, acute, traumatic, subacute and dehisced wounds. SNaP does not use electricity or battery power, instead using "spring and piston technology" to create a constant negative pressure, making it "completely silent", according to Sunnyvale, California-based Spiracur. It is also small enough to fit easily under a patient's clothing, and weighs less than 85g. The firm believes that smaller, more discreet devices can improve patient compliance and improve their quality of life. SNaP was cleared by the US FDA in August 2009 in a new therapy category known as "non-powered" NPWT devices.

Spiracur has CE marked its "ultraportable" SNaP wound care system for sale in Europe. The single-use negative pressure device removes small amounts of fluid from ulcers, surgically closed incisions, and chronic, acute, traumatic, subacute and dehisced wounds. SNaP does not use electricity or battery power, instead using "spring and piston technology" to create a constant negative pressure, making it "completely silent", according to Sunnyvale, California-based Spiracur. It is also small enough to fit easily under a patient's clothing, and weighs less than 85g. The firm believes that smaller, more discreet devices can improve patient compliance and improve their quality of life. SNaP was cleared by the US FDA in August 2009 in a new therapy category known as "non-powered" NPWT devices.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Ryan Nelson

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By Ryan Nelson

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By Marion Webb

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 
• By Natasha Barrow

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

Congress, Researchers Highlight Security Risks At DNA Testing Services

 
• By Elizabeth Orr

Congress has launched an inquiry into 23andMe amid privacy concerns following its bankruptcy, particularly regarding the potential sale of sensitive user data. Additionally, a Cybernews report gave 40 DNA testing firms an average cybersecurity grade of D, citing widespread vulnerabilities and data breaches, along with inadequate public information about their security practices.

Looking Back Towards The Future

 
• By Brian Bossetta

As it celebrates 75 years shaping the medtech industry, Medtronic invited Medtech Insight to its Minneapolis headquarters to get a closer look at the company’s past, what it’s working on now, and what’s on the horizon.

Notified Bodies Warn Of Hurdles In The Way Of Their AI Designations

 
• By Amanda Maxwell

Will challenges in the way of designations of notified bodies that assess AI-enabled medical devices create delays and bottlenecks and slow EU medtech innovation?